SYNH Syneos Health Inc. Class A

Robbins Arroyo LLP: Syneos Health, Inc. (SYNH) Misled Shareholders According to a Recently Filed Class Action

Shareholder rights law firm Robbins Arroyo LLP announces that purchasers of Syneos Health, Inc. (NasdaqGS: SYNH) have filed a class action complaint against the company's officers and directors for alleged violations of the Securities Exchange Act of 1934 between May 10, 2017 and November 8, 2017. Syneos, formerly known as INC Research Holdings, Inc. ("INC"), is an integrated biopharmaceutical solutions company in North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America.

View this information on the law firm's Shareholder Rights Blog: www.robbinsarroyo.com/syneos-health-inc

Syneos Accused of Misleading Investors About its Merger

According to the complaint, on May 10, 2017, INC announced that it was acquiring inVentiv Health, Inc., stating that the merger marks a "significant milestone" for INC and that it would expand the company's global scale. That same day, INC announced purportedly strong business metrics and financial prospects that supported INC's guidance increase. However, the merger did not provide the benefit that INC officials represented because inVentiv was underperforming. On November 9, 2017, INC reported Q3 2017 results that fell far below investors' expectations, including a net loss from operations of $88.9 million, compared to income from operations of $39.4 million for Q3 2016. INC attributed the poor results to previously undisclosed "continued customer and regulatory delays" at inVentiv and lower new drug approval activity during 2016. On this news, INC's stock fell $16.35 per share, or over 28%, to close at $41.15 per share on November 9, 2017.

Syneos Shareholders Have Legal Options

If you would like more information about your rights and potential remedies, contact attorney Leonid Kandinov at (800) 350-6003, [email protected], or via the shareholder information form on the firm's website.

Robbins Arroyo LLP is a nationally recognized leader in shareholder rights law. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits, and has helped its clients realize more than $1 billion of value for themselves and the companies in which they have invested.

Attorney Advertising. Past results do not guarantee a similar outcome.

EN
06/03/2018

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Syneos Health Inc. Class A

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

Syneos Health, Inc.: Update to credit analysis following review for do...

Syneos ratings are on review for downgrade following announcement that it was being acquired by an investment consortium for total purchase price of $7.1 billion, including its existing debt

Moody's places Syneos Health's ratings on review for downgrade on LBO ...

Moody's Investors Service (Moody's) placed Syneos Health, Inc.'s ("Syneos") ratings on review for downgrade. This follows an announcement that Syneos will be acquired by an investment consortium, comprising of Elliott Investment Management, Patient Square Capital and Veritas Capital. The ratings pla...

Syneos Health, Inc.: Update following revision of outlook to negative

Syneos' credit profile reflects its good market position, moderate financial leverage, and strong liquidity, partially offset by operational headwinds.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch